Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BIAF

BIAF - bioAffinity Technologies, Inc. Stock Price, Fair Value and News

$2.12+1.05 (+98.13%)
Market Closed

52/100

BIAF

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

52/100

BIAF

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BIAF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIAF Price Action

Last 7 days

103.9%

Last 30 days

114.1%

Last 90 days

40.4%

Trailing 12 Months

-80.0%

BIAF RSI Chart

BIAF Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIAF Valuation

Market Cap

9.5M

Price/Earnings (Trailing)

-0.65

Price/Sales (Trailing)

1.41

EV/EBITDA

-0.13

Price/Free Cashflow

-1.12

BIAF Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

BIAF Fundamentals

BIAF Revenue

Revenue (TTM)

6.8M

Rev. Growth (Yr)

-38.48%

Rev. Growth (Qtr)

13.91%

BIAF Earnings

Earnings (TTM)

-14.7M

Earnings Growth (Yr)

-152.45%

Earnings Growth (Qtr)

-24.39%

BIAF Profitability

Operating Margin

99.99%

EBT Margin

-216.89%

Return on Equity

-165.57%

Return on Assets

-127.65%

Free Cashflow Yield

-89.2%

BIAF Investor Care

Shares Dilution (1Y)

765.99%

Diluted EPS (TTM)

-20.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20258.8M7.7M6.8M0
20244.9M7.3M9.4M9.4M
20230847.4K1.7M2.5M
20220004.8K
Get all data in R, Python etc through our Historical Stock Data APIs

About bioAffinity Technologies, Inc.

BIAF
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.
 CEO
 WEBSITEbioaffinitytech.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES14

bioAffinity Technologies, Inc. Frequently Asked Questions

BIAF is the stock ticker symbol of bioAffinity Technologies, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of bioAffinity Technologies, Inc. is 9.54 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, BIAF's PE ratio (Price to Earnings) is -0.65 and Price to Sales (PS) ratio is 1.41. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIAF PE ratio will change depending on the future growth rate expectations of investors.